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Purpose: Studies on drugs selected to target myopia development often use the vehicle-treated fellow
eye as a control. However, it is not clear how much of the drug reaches the fellow eye, rendering it a
potentially invalid control. Therefore, in this study, pupil responses were used to probe the effects of atro-
pine in both eyes in mice, after unilateral topical application. In a second experiment, interocular differ-
ences in refractive development and axial eye growth were studied while atropine was applied daily to
one eye.
Methods: In 20 C57BL/6 (B6) wildtype mice, a single drop of 1% atropine solution was instilled into one
eye. Mice were gently restrained by holding their necks while video image processing software detected
the pupil and measured its diameter at a sampling rate of 30 Hz. A bright green LED, attached to the pho-
toretinoscope of the video camera, was ﬂashed. Pupil responses were quantiﬁed daily over a period of 2
weeks. In another group of 24 mice, one drop of 1% atropine was applied daily for 28 days. Axial length
was measured pre- and post-treatment, using low coherence interferometry (the Zeiss AC-Master).
Refractive development was measured by infrared photorefraction.
Results: Similar to previous ﬁndings with the same device, untreated eyes displayed a pupil constriction
of 24.84 ± 1.73% upon stimulation with the green LED. A single drop of 1% atropine caused complete sup-
pression with no signiﬁcant recovery over the whole observation period of two weeks. The responses in
the fellow eye were temporarily reduced to about 75% and then recovered towards baseline. After daily
atropine application, there was signiﬁcant reduction in axial length of the eyes, relative to the saline-trea-
ted fellow eyes (3.234 ± 0.186 versus 3.378 ± 0.176 mm, n = 24, p < 0.01, paired t-test) and the refractions
became more hyperopic/less myopic (+13.46 ± 2.15 D versus +10.06 ± 2.02 D, n = 24, p < 0.01).
Conclusions: In line with previous ﬁndings, one drop of atropine solution caused a long lasting suppres-
sion of pupil responses in the mouse eye. New data show that the transfer to the fellow eye was limited,
making interocular comparisons feasible. It is also new that topical atropine reduced axial eye growth
even when mice had largely normal vision.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Atropine, a pan muscarinic antagonist is used against myopia
progression in children (Chua, Balakrishnan, Tan, & Chan, 2003)
but the intervention is still in an experimental state. A study with
different concentrations (0.1–1%) of atropine eye drops showed
signiﬁcantly lower progression rates compared to the control
group. However, higher doses of atropine were associated with dis-
turbing side effects as mydriasis, photophobia, blurred vision,
allergic dermatitis and systemic interference (Shih, Chen, & Chou,
1999; Shih, Hsiao, & Lin, 2000; Yen, Liu, & Kao, 1989). Lower dosesll rights reserved.
(F. Schaeffel).were better tolerated (Shih et al., 1999). Long-term side effects are
still not well studied (Saw, Gazzard, Au Eong, & Tan, 2002). A study
in Taiwan, involving 188 participants found that atropine, com-
bined with multi-focal lenses, retarded the progression rates of
myopia (Shih et al., 2001) although the mixed treatment makes
it difﬁcult to evaluate the effects of atropine alone.
A larger study was initiated more recently named the ‘‘Atropine
in the Treatment of Myopia (ATOM) study”, which is a randomized,
double-masked, placebo-controlled clinical trial to assess the
safety and efﬁcacy of atropine eye drops in controlling the progres-
sion of myopia in Singapore children (conducted by the Singapore
Eye Research Institute). It was conﬁrmed that atropine treatment
represents an effective way of reducing axial eye elongation during
myopia development. A recent review by Morgan and Megaw
Fig. 1. Original pupil trace as recorded with the infrared photorefractor. In the
bottom, the occurrence of a 80 ms green ﬂash is marked by a vertical line.
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against myopia. Therefore, it is important to better understand
how it prevents axial eye elongation.
Atropine has been extensively tested in animal models. Sup-
pression of deprivation myopia was studied in chicks (McBrien,
Moghaddam, & Reeder, 1993; Schwahn, Kaymak, & Schaeffel,
2000), rhesus monkeys (Tigges et al., 1999; Young, 1965) and tree
shrews (McKanna & Casagrande, 1981). Since the mouse has re-
cently been used as a new model to study myopia (Barathi, Boo-
pathi, Yap, & Beuerman, 2008; Schaeffel, Burkhardt, Howland, &
Williams, 2004), the effects of atropine on pupil responses and
eye growth were studied further. It was found (Schaeffel & Burk-
hardt, 2005) that a single drop has a long-lasting effect on light in-
duced pupil responses.
Since the fellow eye is often used as a control eye for drug treat-
ments, it is important to determine how selective the drug is for
the treated eye. Furthermore, it had not been studied before in
the mouse model or any other animal model whether topical appli-
cation of atropine (rather than intravitreal injection) in one eye can
affect axial eye growth and refractive development, relative to the
other eye.
2. Materials and methods
2.1. Animals
A common black mouse strain, C57BL/6 (n = 20), was obtained
from Charles River GmbH, Sulzfeld, Germany and bred in the
animal facilities of the University of Tuebingen. In addition,
C57BL/6 mice (n = 30) were obtained from the animal holding
unit of the National University of Singapore, which originally
also originated from Charles River. Therefore, data from both
were pooled. Animals were housed in groups of six to eight.
All mice were raised under a 12-h light/12-h dark cycle. Their
treatment was approved by the University Commission of Ani-
mal Welfare in Tuebingen as well as by SingHealth IACUC, and
was in accordance with the ARVO resolution for care and use
of laboratory animals.
2.2. Treatment and numbers of animals
In the ﬁrst experiment, a single drop of 1% atropine solution was
instilled into one eye in the morning of the ﬁrst experimental day.
Twenty mice, 35 days old, were used for this study. In the second
experiment, a single drop of 1% atropine solution was instilled into
the same eye of eight mice every morning for 2 weeks and 16 mice
every morning for 4 weeks. A drop had a measured volume of 33 ll
and contained 330 lg atropine sulfate at a concentration of 1%. In
both experiments, the eyes were treated randomly with some mice
receiving atropine eye drops in the right and some in the left eyes.
In addition, an untreated control group of six mice, 35 days old,
was taken as reference. For the measurements, the mice were
placed on a small, elevated wooden platform and gently restrained
by holding their necks.
2.3. Measurements of the pupil responses and refractive states
Pupillography and measurements of refractive state were per-
formed using infrared photorefraction, performed at 30 Hz sam-
pling rate from a distance of 60 cm in a dim room (ambient
illuminance about 0.3 lux). This technique uses the light of infrared
light emitting diodes to create a brightness gradient in the pupil of
the mouse that is dependent on the refractive error relative to the
camera (Schaeffel et al., 2004). The brightness gradient is automat-
ically quantiﬁed by digital video image processing. Pupillary
responses were elicited by a high power green LED (5 mm diame-ter, 16 cd, peak emmission 520 nm, radiation angle 30, Conrad
Electronics, Hirschau, Germany) attached to the retinoscope which
was controlled from the computer keyboard via a USB to serial port
converter (Schaeffel & Burkhardt, 2005). Stimulation time was
80 ms. The pupil traces were automatically analyzed by a cus-
tom-written software which evaluated the average pupil size in
four measurements before the stimulation and at the point of max-
imal constriction, and which also determined the latency and the
time until the constriction was maximal.
In the ﬁrst experiment, pupillary responses and refractions
were determined after 0.16 h, 0.5 h, 1 h, 3 h, 6 h, 24 h, 36 h, 48 h,
54 h, 72 h, 120 h, 144 h, 168 h, 192 h, 240 h, 336 h. In the second
experiment, pupillary responses and refractions were measured
before and after the daily treatment cycle with atropine, and after
3 h, 168 h, 336 h, 504 h and 672 h.
2.4. Measurement of ocular dimensions
Ocular biometry in the mouse eye requires high spatial resolu-
tion since one diopter of refractive error is equivalent to only about
6 lm (schematic eye modelling: Schmucker & Schaeffel, 2004a) or
24 lm in axial length difference (regression analysis using experi-
mental data: Barathi et al., 2008). Low coherence laser interferom-
etry was used (the Zeiss Meditec ACMaster, Carl Zeiss, Jena) to
measure axial lengths before and after atropine treatment. The de-
vice was originally developed for high-resolution biometry in the
anterior segment of human eyes, but can also resolve differences
of only about 10 lm in axial eye length in living mice. Details on
the method were previously described (Schmucker & Schaeffel,
2004b).3. Results
3.1. Effect of single drop of 1% atropine
The average pupil constrictions of six untreated wildtype mice
were 24.84 ± 1.73%, with an average pupil size before the stimula-
tion of 2.20 ± 0.18 mm. An original trace is shown in Fig. 1.
Analysis of the ranges of pupillary responses in untreated na-
ive mice showed that there were no developmental changes in
the constriction amplitudes over time. The duration of complete
recovery from mydriasis was estimated by ﬁtting a least square
regression through the pupil constriction amplitudes over time
and calculating at which time the regression intersected the
24.84% line, which represented the full amplitude observed in un-
treated mice. Surprisingly, in the eyes treated with atropine, no
signiﬁcant recovery occurred over the observation period of 2
weeks. The responses in the fellow eyes were reduced to 75% over
a period of up to 3 h and recovered only very slowly to baseline
(> 300 h, Fig. 2).
Fig. 2. Average pupil constrictions in percent, elicited by a 80 ms ﬂash of green
light, at different times after unilateral application of 1% atropine eye drops. After
atropine application, the pupillary response was completely suppressed in the
treated eye and also some suppression was noticed in the vehicle treated fellow
eye. The horizontal line on the top represents the amplitudes of pupil responses in
normal mice of the same colony. Error bars denote SEMs (n = 20 mice in the treated
group, and 6 untreated mice).
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4 weeks
In this treatment group, the pupillary responses were com-
pletely suppressed in the treated eye and some suppression was
also noted in the untreated fellow eyes. If the treatment was ex-
tended, the pupillary responses in the saline-treated fellow eyes
were further reduced over time, suggesting that the atropine ef-
fects slowly accumulated (Fig. 3).
A comparison of the pupil responses in the saline-treated fellow
eyes of mice that had received daily atropine versus those which
received only one drop at the beginning showed also signiﬁcant
differences at 3 h, 168 h and 336 h (15.98 ± 0.98% versus
18.03 ± 1.02%; 13.50 ± 0.78% versus 19.26 ± 1.12%; 11.53 ± 1.13%
versus 21.84 ± 0.86%; p < 0.01 in all cases).
Nevertheless, the pupil responses in the saline-treated re-
mained signiﬁcant over the entire treatment period, suggesting
that a gradient of atropine concentrations between both eyes
was maintained. Therefore, an interocular comparison of refractive
development and eye growth appeared feasible and was attempted
as described below.Fig. 3. While the pupil responses in the eyes that received atropine every day
where largely absent (black sockets of the bars), the responses in the fellow eyes
also declined with the total duration of atropine treatment. This suggests that the
atropine effects slowly accumulated (n = 24 in 3, 168 h, 336 h and n = 16 in 504 h,
672 h.3.3. Development of refractive state and axial eye growth with daily
atropine
At the begin of the treatment period of the second group of
mice, selected for daily atropine application, the right eyes had a
tendency to be longer than the left eyes before the treatment
started (n = 24, p = 0.106; Fig. 4A). Nevertheless, eyes were ran-
domly selected for either saline or atropine treatment. After 2
weeks, axial lengths were shorter in the atropine treated eye
(3.309 ± 0.183 mm) as compared to their saline-treated fellow eyes
(3.338 ± 0.162 mm, Fig. 4A). In an unpaired t-test, this was signiﬁ-
cant (n = 24, p < 0.05). Sixteen mice were further treated for an-
other 2 weeks. In this case, axial eye growth was even more
inhibited by atropine (3.278 ± 0.196 versus 3.365 ± 0.148 mm after
3 weeks; 3.234 ± 0.186 versus 3.378 ± 0.176 mm after 4 weeks,
n = 16, p < 0.01).
Refractive state was recorded before and after the treatment
period using infrared photorefraction. In line with other published
data originating from a similar photorefractor (e.g. Pardue et al.,
2008), mice were mildly hyperopic without treatment (Fig. 4B).
At the end of the treatment period, refractive state of the atropine
treated eyes (+13.46 ± 2.15 D) was signiﬁcantly more hyperopic/
less myopic than in the saline-treated fellow eyes
(+10.06 ± 2.02 D, p < 0.01, n = 16). In the atropine-treated eyes,
the pupils were more dilated than in their fellow eyes
(2.61 ± 0.02 versus 2.32 ± 0.05 mm; p < 0.001).
Developmental changes in refractive error in atropine-treated
and saline-treated fellow eyes before and every 2 days after the
beginning of atropine installation are shown in Fig. 5.Fig. 4. Before the treatment period, no signiﬁcant differences were found between
both eyes (gray columns on the right). After two and four weeks of daily instillation
of 1% atropine solution, the treated eyes remained shorter than the saline-treated
fellow eyes (A) and were more hyperopic/less myopic (B). Error bars represent
SEMs. Signiﬁcance levels *p < 0.05, **p < 0.01 (n = 16 animals).
Fig. 5. Refractive error development in atropine treated and their fellow eyes every
2 days after the beginning of daily atropine installation. Atropine- treated eyes
became more hyperopic/less myopic than their saline-treated fellow eyes. Error
bars denote SEMs. At the end, the difference in refraction was signiﬁcant at p < 0.01
(n = 24 animals up to 336 h, and n = 16 thereafter).
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4.1. Special features of the mouse model in drug screenings for myopia
This study has shown that topical application of 1% atropine
solution in one eye reduced pupil responses in both eyes, although
too much lesser extend in the vehicle-treated fellow eye. Large dif-
ferences in pupil responses persisted even if atropine was applied
on a daily regimen, indicating that a gradient in atropine concen-
trations was maintained over the observation period of 2–3 weeks.
Accordingly, it is feasible to compare refractive development and
axial eye growth in both eyes when atropine is applied unilaterally.
A signiﬁcant suppression of axial eye growth was observed in the
atropine-treated eyes, compared to saline-treated fellow eyes. This
result encourages further studies with drugs in mice. Furthermore,
a low number of individuals (n = 24) were sufﬁcient to show signif-
icant differences between both eyes. Perhaps even more encourag-
ing is that axial eye growth was inhibited by topical application of
atropine and not by intravitreal injection – which is necessary in
other animal models like the chicken. A special case in the mouse
is also that axial eye growth is inhibited by atropine even when vi-
sion was largely normal (neglecting potential optical effects of
cycloplegia). In other animal models, the growth-inhibiting effects
of atropine show up most clearly when the eye was deprived of
sharp vision (e.g. McBrien et al., 1993). It is possible that retinal im-
age processing is not so important emmetropization in mice, so
that refractive errors can develop during drug treatment without
that emmetropization attempts to compensate the error signal.
4.2. Optimal concentrations of atropine for cycloplegia in mice
In an earlier study, three different concentrations of atropine
were tested in themouse eyes to induce an optimal effect on the pu-
pil response. All three tested concentrations (0.1%, 0.5%, or 1%) had
severe effects on pupil responses in the treated eye but the time of
recovery towards baseline was dependent on the concentrations
(Schaeffel & Burkhardt, 2005). In the present study, only the highest
dose was tested because it was assumed that potential effects of
atropine on the contra-lateral eye would show up most clearly.
4.3. Use of atropine and antimuscarinic therapy for myopia
retardation
To date atropine has shown to be a promising pharmacological
agent that has signiﬁcantly reduced the progression of myopia in
several clinical trials (Shih et al., 1999; Chou, Shih, Ho, & Lin,
1997, and others) However, the molecular basis of atropine actionis yet to be established. Previous analyses agree that the required
doses of atropine are much too high to assume a muscarinic recep-
tor-mediated mechanism. This assumption receives further sup-
port by the observation that atropine is extremely effective on
the pupil in mice (Schaeffel & Burkhardt, 2005), but has effects
on eye growth only at very high doses (this study).
4.4. Scleral connective tissue and muscarinic receptors
In this study we have found that the axial length is only
slightly reduced in the treated eyes by daily atropine treatment
for 2 weeks. It was further reduced if the treatment was contin-
ued for another week. There is extensive literature on animal
and human myopia studies, but the role of muscarinic receptors
remains uncertain (Chua et al., 2006). At least, other muscarinic
antagonists were also found effective although, again, the re-
quired doses were very high (pirenzepine: Tan, Lam, Chua,
Shu-Ping, & Crockett, 2005). Axial elongation is believed to have
been mediated by alterations in the connective tissues of the
sclera (McBrien & Gentle, 2001; Raghunath et al., 1999), the ﬁ-
brous coat in the eye. Hence, modulation of connective tissue
molecules in the sclera may represent a strategy for arresting
all types of myopia development, regardless of the initiating
stimulus. It was shown that application of atropine reduces the
production of scleral extracellular proteins. Anti-muscarinic
drugs were able to change collagen and other structural mole-
cules in animal models of myopia (Lind, Chew, Marzani, & Wall-
man, 1998; McBrien, Metlapally, Jobling, & Gentle, 2006). This
also suggests that investigation of scleral remodeling by atropine
in the mouse model may be a good strategy to discover other
anti-myopiagenic drugs for humans.
4.5. Conclusions
In mice, atropine caused a long lasting suppression of pupillary
responses in treated eyes with little transfer to the saline-treated
fellow eyes. Eyeball enlargement was signiﬁcantly reduced by
atropine if continued for 2 weeks or longer, and this happened
even when the mice had largely normal vision. That no intravitreal
application was necessary, and the effects were signiﬁcant with a
relatively low number of mice, appears promising. The blockade
of parasympathetic synaptic transmission in the ciliary muscle
by atropine is extremely effective, compared to its inhibition of
myopia development – both in animal models and children. This
suggests that different mechanisms or receptor types are involved
in mydriasis versus myopia suppression.Disclosure
None for all the authors.
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